Compare COCH & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | COCH | CCIF |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Finance/Investors Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 53.4M |
| IPO Year | 2021 | 2011 |
| Metric | COCH | CCIF |
|---|---|---|
| Price | $0.65 | $2.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.17 | N/A |
| AVG Volume (30 Days) | 57.0K | ★ 137.1K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | ★ 17.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.11 | N/A |
| 52 Week Low | $0.36 | $2.20 |
| 52 Week High | $1.02 | $5.49 |
| Indicator | COCH | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 29.03 |
| Support Level | $0.63 | $2.20 |
| Resistance Level | $0.74 | $2.48 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 1.36 | 12.90 |
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.